Y-mabs announces update on omburtamab in dipg

New york, nov. 19, 2020 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced a clinical update on omburtamab for the treatment of diffuse intrinsic pontine glioma (“dipg”). data was presented at the society for neuro-oncology (“sno”) virtual annual meeting held november 19 through november 21, 2020. the omburtamab data was presented by dr. evan bander from weill cornell medicine.
YMAB Ratings Summary
YMAB Quant Ranking